Zealand Pharma A/S is a Denmark-based biotechnology company specializing in the discovery and development of peptide-based medicines for metabolic and gastrointestinal diseases. Its research focuses on engineered hormone analogs and other peptide therapeutics addressing obesity, type 2 diabetes, rare endocrine disorders, and related cardiometabolic conditions.
The company advances a pipeline from preclinical to late-stage clinical programs and has a track record of originating approved products via partners, including the GLP-1 receptor agonist lixisenatide and the glucagon analog dasiglucagon. Zealand Pharma combines in-house peptide design and formulation expertise with clinical development and strategic collaborations to progress candidates and, where appropriate, out-license commercialization to larger pharmaceutical companies.
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
Trial met co-primary endpoints; 85.1% achieved ≥5% weight loss vs 38.8% placebo; weight loss mainly fat with reduced waist circumference; GI events were mild–moderate; MASH trials ongoing
Petrelintide shows significant weight loss and good tolerability in Phase II trial, supporting further development for chronic weight management.
Petrelintide shows significant weight loss and good tolerability in Phase II trial, supporting further development for chronic weight management.
